The "synactive" theory of neurobehavioral development, introduced by Als in the late 1970s, forms the basis of the Newborn Individualized Developmental Care and Assessment Program (NIDCAP). 1, 2 It requires trained and certified caregivers to use the Assessment of Premature Infant Behavior (APIB) tool to observe 91 neonatal behaviors every 2 minutes for 1 hour before, during, and after a caregiving intervention. After the assessment, recommendations for caregiving are provided to the bedside nurses and the infant' s family. Although individualized, the caregiving principles to reduce stress and promote physiologic stability are often generalized to include alteration of the environment (lower ambient light and sound), aids to promote flexion and self-regulation, clustering of care, and parental involvement in the care of their infant.
The first published NIDCAP study hypothesized that the respiratory and functional states of the very low birth weight infants at risk for bronchopulmonary dysplasia would be improved by preventing inappropriate sensory input. 3 This phase-lag study lacked power, enrolling only 16 infants over 2 years. Baseline characteristics favored the NIDCAP group, suggesting very selective enrollment. Some outcomes reported had occurred in the NIDCAP group before initiation of the study intervention. 4 Since then, several small unmasked randomized controlled trials (RCTs) assessing the effectiveness of NIDCAP in improving either short-term medical and/or neurodevelopmental outcomes have been published. Since 1993, systematic reviews of NIDCAP have been conducted. [4] [5] [6] [7] [8] [9] [10] [11] Reviewers agree that, based on small sample sizes and poor study quality, there was insufficient high-quality evidence regarding the NIDCAP on which to base clinical practice and that further well-conducted RCTs were needed. Several larger trials were published from 2009 to 2012 justifying this update of our previous reviews. 4, 5, 8 
OBJECTIVES
To assess the effectiveness of NIDCAP in improving short-term medical and long-term neurodevelopmental outcomes in preterm infants based on published RCTs. 
METHODS
We followed the "Preferred reporting items for systematic reviews and metaanalyses" (PRISMA) statement for reporting of this systematic review 18 and the format of our previous systematic reviews. 4, 5, 8 To be included in the review, the intervention had to be NIDCAP as described by Als 1-3 and applied to low-birth-weight or preterm infants while in the hospital. The intervention had to be tested in a RCT design and compared with standard care. At least 1 of the short-or longterm outcomes described above had to be reported. No language restrictions were applied.
Search Strategy
Manual searches were conducted of personal files and reference lists from our previously published reviews on NIDCAP. 4 If at least 2 studies reported the same outcome, meta-analyses by the use of RevMan 5.1 were performed. 20 The fixed-effects model was used. For dichotomous outcomes, the relative risk (RR) is reported. If the RR was statistically significant, the risk difference was to be reported. If the risk difference was statistically significant, we planned to report the number needed to treat to benefit or to harm. For continuous outcomes, the mean difference (MD) is reported. The standardized mean difference was used when in different studies the same construct was measured by using different scales of measurement. For all estimates, the 95% confidence intervals (CI) are reported. Heterogeneity was measured by using the I 2 test and I 2 values of ,25%, 25% to 49%, 50% to 74%, and $75% were assigned not important, low, moderate, and high heterogeneity, respectively. 22 Sensitivity analyses were conducted in an attempt to explain heterogeneity. When means and SDs were not reported in the primary reports, we contacted the authors to provide the information, or means and SDs were estimated by Dr Shafagh Fallah, Statistician, from reported medians, ranges and sample sizes.
RESULTS
The search strategy identified 11 trials 19,23-32 and 7 secondary (follow-up) studies. [33] [34] [35] [36] [37] [38] [39] The flow of the searches and the number of included 19, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] and excluded [40] [41] [42] [43] [44] [45] studies are described in 28 included data from 3 trials conducted at the Brigham Women's Hospital (BWH); Als 1994 study, 19 which was conducted at the BWH; the trial at the BWH site in Als 2003 3-site study 26 ; and 1 trial at the BWH not previously published. As did the authors, we report separately on the 2 additional sites in the Als 2003 study 26 conducted at Children's Hospital Boston (CHB) (Als CHB 2003) and at Children's Hospital Oakland (CHO) (Als CHO 2003) . Five trials including 6 reports were excluded because 1 trial did not report results per groups randomized, 40 one trial (2 reports) 41, 42 tested only part of the NIDCAP intervention (covers and nesting), 1 trial 43 tested a developmental intervention offered to the mothers, and 2 trials tested the NIDCAP intervention during stressful/painful interventions. 44, 45 We obtained unpublished data or clarification of aspects of the trials from several authors/coauthors for this or previous reviews (Als, Buehler, Fleisher, Maguire, Tyebkhan, and Westrup).
Characteristics of the included studies are presented in Supplemental Appendix 1, and the "Risk of Bias" is reported in Supplemental Appendix 2. The 11 identified trials included 627 neonates for which baseline criteria were reported. There were no statistically significant differences between the NIDCAP and the control group for 2 important baseline criteria, birth weight and PMA at birth (birth weight MD 9 g [95% CI 223 to 42] and PMA at birth MD 0.18 weeks [95% CI 20.06 to 0.43]).
The quality of the included trials varied (Supplemental Appendix 2). Adequate randomization sequence generation was reported in 2 studies. 29, 30 There was low risk of bias for allocation concealment because all but 2 studies 26, 28 reported the use of sealed envelopes. There was high risk of bias in all studies for blinding, because the NIDCAP intervention cannot be blinded to personnel, parents, and assessors of most outcomes. There was a low risk for bias regarding addressing incomplete outcome data in 4 studies, 23, [28] [29] [30] with unclear risk in 3 studies 19, 24, 31 and high risk in 4 studies. [25] [26] [27] 32 The risk of selective reporting was unclear for all studies, because no study was entered into a trials registry until after the last infant had been recruited. The risk of other sources of bias was unclear in 6 studies 19, [26] [27] [28] 31, 32 and low in 5 studies. [23] [24] [25] 29, 30 In many of the studies by Als' group there was a long delay (up to 20 years, or more) between infant recruitment and study publication. The 2 studies by Peters et al 30 and Maguire et al 29 published in 2009 were of the highest quality and had the largest sample sizes.
Primary and Secondary Long-Term Outcomes
Of the 2 primary outcomes, "The composite of death or major sensorineural disability at 18 months CA or later in childhood" did not differ significantly between the groups (3 trials 302 children; RR 0.89 [95% CI 0.61 to 1.29]). There was high heterogeneity for this outcome (I 2 = 79%). Our second primary outcome, "Survival free of disability at 18 months CA or later in childhood," was not significantly different between the 2 groups (2 trials, 192 infants RR 0.97 [95% CI 0.69 to 1.35]). There was no heterogeneity for this outcome (I 2 = 0%) ( Table 1 ; Fig 2) .
Secondary long-term outcomes at or beyond 18 months CA did not differ significantly between the groups for visual impairment, sensorineural hearing loss, or cerebral palsy. One study found no significant difference in health-related quality of life at 12 months of age. 39 
Neurodevelopmental Outcomes From 4 Months CA to 8 Years of Age
There were no significant differences in BSID-MDI and BSID-PDI scores at 4 months CA. At age 9 or 12 months CA, the BSID-MDI and BSID-PDI scores were significantly higher in the NIDCAP group. As seen in Figs 3 and 4 and Table 2 , the statistically significant differences were seen at 9 months CA, but not at 4, 12, 18, or 24 months CA. There was high and moderate heterogeneity for these outcomes (I 2 of 76% and 56%, respectively). Full-scale, verbal, or performance IQ at 5.5 or 8 years of age did not differ significantly between the NIDCAP and control groups.
Short-term Medical Outcomes
No significant differences were found in the rates of in hospital deaths, CLD at 36 weeks PMA, intraventricular hemorrhage (all grades and grades III/IV), sepsis, retinopathy of prematurity (all stages and stages $3) and necrotizing enterocolitis, nor in the duration of supplemental oxygen and days of assisted ventilation via an endotracheal tube (Table 3) (Fig 6) , resulted in a nonsignificant MD of 0.36 weeks (20.88 to 0.15) with no important heterogeneity (I 2 = 9%). Thus, the between-study heterogeneity could be explained by the 2 outliers.
Growth
There were no significant differences in head circumference at term or 2 weeks CA, nor at 9 months, 1 year and 2 years CA. There was a significant difference in daily weight gain in hospital of 1.5 g (95% CI 0.3 to 2.6), but no difference in weight at term, 2 weeks, 9 months, 1 year, and 2 years CA (Table 4) .
Prechtl and APIB Scores
In the studies by Als group, the results of Prechtl and APIB scores performed at 2 weeks CA favored the NIDCAP group (Supplemental Appendix 3). In the latest study by Als et al, 32 different categories for the APIB assessment compared with previous studies were used, such that we were not able to include this study (Supplemental Appendix 1). The results favored the NIDCAP group. In the study by Maguire 2009 a definitely abnormal Prechtl score was more common in the NIDCAP group. 38 
Sleep Outcomes
Percentage of time spent in quite sleep at 32 and 36 weeks PMA, percentage during day and night time at 36 weeks PMA, and at 3 months of age did not differ significantly between groups (Supplemental Appendix 4).
DISCUSSION
We set out to answer 2 questions: (1) Does NIDCAP improve long-term
FIGURE 2
Death or disability at 18 months CA or later in childhood. M-H, Mantel-Haenszel. Likewise, a daily weight gain of 1.5 g (95% CI 0.3 to 2.6 g) during hospitalization is not clinically important, especially because there were no differences in weight at term, 2 weeks, 9 months, 1 year, and at 2 years CA ( Table 4 ). The only other significant findings were a 6-day reduction in hospitalization (95% CI 211 to 21.5 days) with a related 0.5-week reduction in PMA at discharge (95% CI 21.02 to 20.00). There was moderate heterogeneity for both of these outcomes, with the same 2 clear outliers identi- (Figs 5 and 6 ). In sensitivity analyses excluding these 2 studies, statistical significance disappeared for both outcomes. At study entry, the PMA favored the NIDCAP group by 0.18 weeks (95% CI 20.06 to 0.43), offsetting the findings in PMA at discharge. There were no statistically significant differences in any other medical and neurodevelopmental
FIGURE 3
Bayley scales of infant development: mental development index at 9 or 12 months corrected age.
FIGURE 4
Bayley scales of infant development: psychomotor development index at 9 or 12 months corrected age. outcomes between the NIDCAP and control groups. Given the large number of outcomes, one would expect a few to reach statistical significance by chance. Because NIDCAP was not effective in reducing adverse outcomes, performing cost-effectiveness analyses became redundant.
The quality of the included trials varied, with the 2 largest trials having the lowest risk of bias. 29, 30 These 2 studies reported conflicting results. 46, 47 The intervention did not appear to differ in the Canadian study, which showed shorter length of hospitalization, 30 compared with the Dutch study. 29 The NIDCAP intervention cannot be blinded. There were remarkably long time periods between the conduct and publication of many trials. 19, 26, 28, 31 None of the RCTs were registered before the recruitment of the last infant, making it impossible to ascertain whether the selection of primary outcomes was made at the design stage of the trial or after data had been collected.
Other published systematic reviews, comprising fewer studies and infants, have not identified a clear benefit of NIDCAP. [4] [5] [6] [7] [8] [9] [10] [11] In our first review published in 1993, only 1 phase-lag NIDCAP study (not an RCT) of 16 infants was identified. 4 In our second review published in 2002, including 5 RCTs enrolling 136 infants, we found a significant benefit of NIDCAP on number of 
FIGURE 5
Length of hospitalization (days).
FIGURE 6
Postmenstrual age (weeks) at discharge from the hospital. days of supplemental oxygen, days on assisted ventilation, and improved neurodevelopmental outcome at 9 or 12 months but not at 2 years CA. 5 The 2006 update of Symington and Pinelli' s Cochrane review included 5 trials, 6 one of which was the 1986 phase-lag study by Als et al. 3 Outcomes were reported for a maximum of 4 trials with a total of 105 infants, with a reduction in days on assisted ventilation. 6 Our 2007 update, published in Swedish, included a total of 6 studies with a maximum of 330 infants reported in any 1 outcome. 8 We noted significant reductions in CLD at 36 weeks PMA, days on assisted ventilation, days in hospital, PMA at discharge, and daily weight gain. Wallin and Eriksson conducted a systematic review, but not meta-analysis, and included only studies that showed a statistically significant difference in an outcome. 9 They concluded: "….the scientific evidence on the effects of NIDCAP is limited. Shortcomings in design and methods in the reviewed studies hamper far-reaching claims on the effectiveness of the method." Vanderveen et al 10 included 5 NIDCAP trials with a maximum of 43 infants for any reported outcome. They found a significant increase in BSID-MDI at 12 months CA in the NIDCAP group, but not at 24 months CA or in WPPSI-R at 5 years of age. BSID-PDI was not significantly better at any age. In our current review with the largest number of included infants and maximum number of 566 infants reported in any 1 outcome, the number of statistically significant outcomes are fewer and cannot be considered to be clinically important.
The findings and conclusions of these systematic reviews are in sharp contrast to the statements by proponents of NIDCAP. 48 The NIDCAP Federation International claims that "Research has documented the beneficial effect of NIDCAP in terms of shorter intensive care and overall hospital stay, better weight gain and improved behavioral outcomes that endure beyond infancy. Studies have also documented that the NIDCAP approach enhances brain structure and function when measured by sophisticated medical techniques such as EEG and MRI." 48 We did not include neurophysiological or neuroimaging outcomes as they are surrogate biomarkers for long-term neurodevelopment, and were only reported in a limited number of trials with possible selection bias (all randomly assigned infants did not undergo all the tests).
We stated in our 2002 systematic review that "modification of the extrauterine NICU environment and caregiving according to each infant' s current physiologic and neurobehavioral functioning is a rational and intuitive approach to caring for preterm infants and their families and to supporting infant development." 5 The NIDCAP is 1 clinical framework and training program to provide individualized developmental care to vulnerable preterm infants. NIDCAP is resource-consuming, labor-intensive, and expensive both to implement and maintain, because it requires developmental specialists, regular APIB assessments, and training of nursing staff. 49 Gibbins et al 50 recently proposed a new conceptual developmental care model "of a shared surface, manifested most obviously by the skin that forms the critical link between the body/organism and the environment and becomes the focal point of human interactions." To our knowledge, this model has not been rigorously investigated. Innovative interventions to promote development in preterm infants should be tested in large welldesigned RCTs and their results published in a timely fashion. Before any further research of developmental care is undertaken, consideration should be given to reports that many NIDCAP behaviors are rarely or never seen among preterm infants, 51 that only a few are associated with stressful/ painful interventions, 52 and that clustering of care can result in important behavioral and autonomic reactions. 53 Two commonly recommended interventions as part of NIDCAP are incubator covers and nesting, which have not been shown to be effective in improving developmental outcomes. 42 Cycled lighting, as opposed to dim lighting or near darkness, may have beneficial effects on infants' fussing and crying behavior and growth in the first weeks of life. 54, 55 Because we were not able to identify any clear benefits of NIDCAP for long-term neurodevelopmental outcomes, nor for any short-term medical outcomes, we cannot recommend the implementation of NIDCAP in its present form as standard care in preterm infants. performed at 2 weeks CA." On page e891, under the Discussion heading, paragraph 2, line 15, the copy reads: "NIDCAP is resource-consuming, labor-intensive, and expensive both to implement and maintain, because it requires developmental specialists, regular APIB assessments, and training of nursing staff. 49 " This should have read: "NIDCAP is resource-consuming, labor-intensive, and expensive both to implement and maintain, because it requires developmental specialists, regular NIDCAP assessments, and training of nursing staff. 49 " doi:10.1542/peds.2013-1158
